# ScreenIn3D

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/screenin3d

- Industry: Biotechnology
- Headquarters: Glasgow, UK
- Website: www.screenin3d.com/
- Total disclosed funding: $1M
- Latest round: Seed (Jun 12, 2025)
- Investors on record: 5

## About

Based in the UK, ScreenIn3D Ltd specializes in advanced precision therapy screening technologies, enhancing patient outcomes through innovative modeling solutions for healthcare professionals.ScreenIn3D Ltd, founded in 2018 and headquartered in Glasgow, UK, focuses on developing technologies for precision therapy screening. The company has successfully completed one funding round, raising GBP 750,000 in Seed funding in June 2025, led by TRICAPITAL with contributions from investors such as Gabriel Investments and Scottish Enterprise. The founder's history is not specified, and there are no mentions of pivots or changes in business strategy.ScreenIn3D Limited specializes in advanced precision therapy screening technologies, focusing on enhancing patient outcomes through innovative modeling solutions. Their core offerings include a suite of 3D screening tools and disease models to assist healthcare professionals in diagnosing and treating various medical conditions. This technology enables users to visualize complex biological processes, ultimately aiding in personalized treatment strategies. ScreenIn3D serves a diverse client base, including healthcare providers, research institutions, and pharmaceutical companies across Europe and North America, with applications in oncology, neurology, and other critical therapeutic areas.ScreenIn3D Limited generates revenue through direct business-to-business transactions, primarily through partnerships that integrate their solutions into existing healthcare frameworks. Revenue is derived from subscription-based licensing agreements for software solutions and one-time fees for specialized 3D models. Their flagship product, UpScale 3D technology, is priced based on the complexity and application requirements of the models requested, facilitating steady revenue streams and fostering long-term collaborations with healthcare providers and research organizations.In June 2025, ScreenIn3D Ltd raised GBP 750,000 in Seed funding led by TRICAPITAL, which will be used to scale operations, increase staff, and expand its technology to other disease areas. The company aims to launch new products tailored for additional medical applications and plans to explore expansion into specific markets including Asia and Africa by 2026.

## Funding rounds

- Seed, Jun 12, 2025, $1M — University of Strathclyde, Gabriel Investments, Scottish Enterprise, Nidobirds Ventures, TRICAPITAL

## Investors

- University of Strathclyde — Seed
- Gabriel Investments (https://capitalatlas.ai/funds/gabriel-investments) — Seed
- Scottish Enterprise (https://capitalatlas.ai/funds/scottish-enterprise) — Seed
- Nidobirds Ventures (https://capitalatlas.ai/funds/nidobirds-ventures) — Seed
- TRICAPITAL (https://capitalatlas.ai/funds/tricapital) — Seed